Biocon Biologics’ First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts’ Largest Formulary in US
-
Thu, 21-Oct-2021
- Posted by: Biocon Biologics
No Comments
Biocon Biologics Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection
-
Sat, 25-Sep-2021
- Posted by: Biocon Biologics
Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance
-
Thu, 16-Sep-2021
- Posted by: Biocon Biologics
Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
-
Thu, 29-Jul-2021
- Posted by: Biocon Biologics
Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19
-
Mon, 26-Jul-2021
- Posted by: Biocon Biologics
Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr;
-
Fri, 23-Jul-2021
- Posted by: Biocon Biologics
Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68%
-
Thu, 29-Apr-2021
- Posted by: Biocon Biologics
Biocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facility of the Year Honorable Mention Award
-
Wed, 28-Apr-2021
- Posted by: Biocon Biologics
Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.
-
Wed, 28-Apr-2021
- Posted by: Biocon Biologics
Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab
-
Mon, 26-Apr-2021
- Posted by: Biocon Biologics
